focus -WSS

focus

author：Wikipedia 2025-09-28 00:50:08 - browse：54

Sen. Bill Cassidy, R-La., listens during a Senate Health, Education, Labor, and Pensions Committee hearing. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Stefani Reynolds/The New York Times via AP

WASHINGTON — The top-ranking Republican on the Senate health committee is launching an investigation into two hospitals’ use of a government program that provides big drug discounts in return for serving low-income communities.

At the foundation of the debate over the so-called 340B program is whether Congress intended it to directly benefit low-income and uninsured patients or whether it was meant to help finance those hospitals, which could use the money as they see fit to add services.

Hospitals say they use the money to provide such services as free care for uninsured patients, free vaccinations, mental health clinics, and community health programs. But drugmakers have long argued that hospitals and chain pharmacies abuse the program and divert its cash flows to other uses. They also say the 340B program fuels the consolidation of health care systems as hospitals buy up private doctor practices to expand the 340B revenue stream.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

entertainment

WSS

FDA's naming rule on biosimilars has undermined competition

CRISPR gene editing developments we’re watching in 2024

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Decaf coffee targeted by food safety group under obscure FDA rule

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

hotspot

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

HCA sued by state AG for quality issues at Mission Health

Medicare proposal to cover medical devices draws a mixed reaction

CRISPR gene editing developments we’re watching in 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast: mifepristone case, GLP

Medical records are filled with copy

HCA sued by state AG for quality issues at Mission Health

hotspot

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Carvykti CAR

Editas, Vertex strike deal on CRISPR

Grail spinoff by Illumina should end disastrous merger attempt

There's no autism epidemic. It's an autism diagnosis epidemic

SEC charges former device maker CEO with $41 million fraud

leisure time

explore

entertainment

leisure time